C4 Therapeutics, Inc.

NASDAQ:CCCC

2.02 (USD) • At close March 13, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q4
Revenue 5.17715.36212.0063.0393.26111.0722.6643.7592.8546.75413.8347.65420.0788.59.7817.4268.2628.4479.676.8168.2095.3643.9043.904
Cost of Revenue 02.0562.0452.0271.6911.9951.9892.0622.0231.9192.1411.4890.75824.30223.28620.52619.46123.93517.7616.31216.01712.9489.5479.547
Gross Profit 5.17713.3069.9611.0121.579.0770.6751.6970.8314.83511.6936.16519.32-15.802-13.505-13.1-11.199-15.488-8.09-9.496-7.808-7.584-5.643-5.643
Gross Profit Ratio 10.8660.830.3330.4810.820.2530.4510.2910.7160.8450.8050.962-1.859-1.381-1.764-1.355-1.834-0.837-1.393-0.951-1.414-1.446-1.446
Reseach & Development Expenses 32.51331.83823.75322.53330.39128.34729.92629.04230.65229.66331.32326.20326.55124.30223.28620.52620.43323.93517.7616.31216.01712.9489.5479.547
General & Administrative Expenses 10.37311.7689.69510.28810.29710.53310.30610.94510.4959.5799.89512.828.7828.4528.6117.4096.7322.8612.7692.8422.6912.4171.8341.834
Selling & Marketing Expenses 0000-1.6910000000000000000000
SG&A 10.37311.7689.69510.2888.60610.53310.30610.94510.4959.5799.89512.828.7828.4528.6117.4096.7322.8612.7692.8422.6912.4171.8341.834
Other Expenses 0002.43700000000000000.043000.002-0.00100
Operating Expenses 42.88643.60633.44835.25838.99738.8840.23239.98741.14739.24241.21839.02335.33332.75431.89727.93527.16526.79620.52919.15418.70815.3651.6871.687
Operating Income -37.709-28.244-21.442-32.219-37.427-27.808-37.568-36.228-38.293-32.488-27.384-31.369-15.255-24.254-22.116-20.509-18.903-18.349-10.859-12.338-10.499-10.001-7.477-7.477
Operating Income Ratio -7.284-1.839-1.786-10.602-11.477-2.512-14.102-9.638-13.417-4.81-1.979-4.098-0.76-2.853-2.261-2.762-2.288-2.172-1.123-1.81-1.279-1.864-1.915-1.915
Total Other Income Expenses Net 3.2673.5783.7261.4212.951.7741.6461.4481.1080.53-0.028-0.251-0.403-0.429-0.464-0.462-3.016-3.653-0.1020.2590.380.5570.6110.611
Income Before Tax -34.442-24.666-17.716-28.361-34.477-26.034-35.922-34.78-37.185-31.958-27.412-31.62-15.658-24.683-22.58-20.971-21.919-22.002-10.961-12.079-10.119-9.444-6.866-6.866
Income Before Tax Ratio -6.653-1.606-1.476-9.332-10.573-2.351-13.484-9.252-13.029-4.732-1.981-4.131-0.78-2.904-2.309-2.824-2.653-2.605-1.134-1.772-1.233-1.761-1.759-1.759
Income Tax Expense 0.1310-2.045-2.0270.277-1.0031.788-0.842-1.108-0.530.0280.2510.5390.110.0690.072-0.124-0.167-0.168-0.167-0.0960.650.1250.125
Net Income -34.573-24.666-17.716-28.361-34.754-27.037-35.922-33.938-36.077-31.428-27.44-31.871-15.658-24.683-22.58-20.971-21.795-21.835-10.793-11.912-10.023-10.094-9.091-9.091
Net Income Ratio -6.678-1.606-1.476-9.332-10.657-2.442-13.484-9.028-12.641-4.653-1.984-4.164-0.78-2.904-2.309-2.824-2.638-2.585-1.116-1.748-1.221-1.882-2.329-2.329
EPS -0.49-0.35-0.26-0.41-0.68-0.55-0.73-0.69-0.74-0.64-0.56-0.66-0.32-0.51-0.51-0.49-0.53-0.54-0.26-0.69-0.58-0.59-6.76-6.76
EPS Diluted -0.49-0.35-0.26-0.41-0.68-0.55-0.73-0.69-0.74-0.64-0.56-0.65-0.32-0.51-0.51-0.49-0.53-0.54-0.26-0.69-0.58-0.59-6.76-6.76
EBITDA -33.962-22.61-15.671-26.334-32.786-23.872-33.333-32.112-34.561-29.485-24.737-29.604-14.361-23.814-21.332-19.666-20.41-20.717-10.443-11.663-10.077-9.58-7.101-7.101
EBITDA Ratio -6.56-1.472-1.786-10.602-10.959-2.512-13.259-9.091-12.636-4.588-1.911-4.022-0.737-2.802-2.214-2.691-2.174-2.141-1.077-1.711-1.228-1.786-1.819-1.819